: iStockAnalyst.com Symbols Feed

FDA Calendar Extreme Trades: 85 Single Digit Stocks

Tue, 13 Oct 2009 16:29:25 GMT

The BioMedReports.com FDA Calendar database includes over 400 entries of (1) pending new drug, biological agent, or medical device new product decisions at the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, and sBLA filings); (2) pending new submissions to the FDA; (3) pending complete response letter (CRL) re-submissions to the FDA; and (4) pending clinical trial results.[More...]

Best Performing Stocks - Third Quarter 2009

Thu, 01 Oct 2009 13:27:51 GMT

Here is a look at the top scorchers of the third quarter; a period where the S&P 500 gained 15% - it's best return since we were building the last stock market bubble in 2008. Who says history does not repeat itself?[More...]

Salix Pharmaceuticals (NASDAQ: SLXP): Notable Momentum

Tue, 15 Sep 2009 13:25:00 GMT

Salix Pharmaceuticals (NASDAQ:SLXP) closed Friday at $13.38. The stock crossed earlier 52-week high of $13.99 and touched a new 52-week high at $21.34 in Monday’s morning trade.[More...]

Market Closing: Stocks Manage Narrowly Higher Finish Thanks To Late Move

Mon, 14 Sep 2009 20:25:00 GMT

A late-day charge landed the major averages in positive territory, closing up around 0.2% to 0.5%. European indexes fell on Monday for the first time in eight days. Japanese and Hong Kong stocks slipped as investors feared that the strong yen would dent Japanese exporters' earnings.[More...]

FDA, Clinical Trial Updates: BIIB, SLXP, CTIC, PFE, Roche (OTC:RHHBY)

Wed, 20 May 2009 15:26:00 GMT

Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, s (...)[More...]

FDA, Clinical Trial Calendar Updates: WYE, SVNT, AMRN, ISIS, SLXP, SOMX

Fri, 08 May 2009 15:51:00 GMT

Salix Pharmaceuticals - Bear of the Day

Wed, 22 Oct 2008 14:41:00 GMT

Salix Pharmaceuticals is focused on drugs used in the treatment of a variety of gastrointestinal diseases. The company is facing difficult times thanks to the FDA's approval to three generic versions of lead product, Colazal. As such, we expect 2008 to be an extremely challenging year for the company, with a significant decline in top-line growth. Moreover, we expect the company to post a loss in 2008 and 2009. We believe that the main potential for the company lies with the approval of additional indications for Xifaxan, particularly the irritable bowel syndrome (IBS) indication. However, we were disappointed to hear that Salix expects to file the NDA (new drug application) for the IBS indication in mid-2010, a significant delay from the previously announced timeline of late 2008 / early 2009. While new product approvals should help restore investor confidence, the possibility of a patent challenge for Xifaxan will remain an overhang on the shares in the[More...]

Salix Pharma Hurt by Generics - Analyst Blog

Mon, 20 Oct 2008 18:30:00 GMT

Salix Pharma (SLXP) is focused on drugs used in the treatment of a variety of gastrointestinal diseases. The company is facing difficult times thanks to the FDA's approval to three generic versions of lead product, Colazal. As such, we expect 2008 to be an extremely challenging year for the company, with a significant decline in top-line growth. Moreover, we expect the company to post a loss in 2008 and 2009. We believe that the main potential for the company lies with the approval of additional indications for Xifaxan, particularly the irritable bowel syndrome (IBS) indication. However, we were disappointed to hear that Salix expects to file the NDA (new drug application) for the IBS indication in mid-2010, a significant delay from the previously announced timeline of late 2008 / early 2009. [More...]

Analyst Comments: Align Tech, DeVry, Eni SpA, Finisar, Hospira, McDonald, Cleveland-Cliffs, Marlin Biz, Mobile TeleSystems, Salix Pharma, Potash Corp

Wed, 10 Sep 2008 21:42:00 GMT

We believe a difficult U.S. economy and higher marketing expenses will hamper Align Tech, Inc.?s (ALGN) topline growth and margins. Strong international growth and foreign exchange gains will help offset this. In the near-term, we think earnings quality could become an issue as the management finds it difficult to meet growth targets. Meaningful earnings growth will be pushed out to fiscal 2009 and 2010. We are reiterating the current Hold recommendation. We have adjusted our models to reflect the current economic environment. We expect fiscal 2008 sales growth of 10%, in-line with the management?s guidance of $309 million - $314 million. Heavier marketing spending may be necessary to drive GP channel penetration required to achieve management s growth targets. As a result, margin pressure can be expected, possibly leading to earnings quality issues.[More...]

Analyst Comments: Optimer Pharma, CREE, Delphi Financial, VeraSun, InterDigital, Greenfield Online

Thu, 14 Aug 2008 05:05:00 GMT

Optimer Pharmaceuticals, Inc. (OPTR) is a biopharmaceutical company specializing in anti-infective drug development and commercialization.[More...]

Salix Reports Stronger Drug Sales

Wed, 06 May 2009 18:25:00 GMT

May 6--Salix Pharmaceuticals reported a first-quarter loss, but sales of its medicines to treat gastrointestinal ailments rose 30 percent.
The Morrisville company released its latest financial results late Tuesday.
Salix products are used to treat ulcerative colitis, travelers' diarrhea and other diseases.

[More...]

Salix Reports Surge in Q4 Revenues

Tue, 10 Mar 2009 20:21:11 GMT

Raleigh, North Carolina-based developer and marketer of prescription medical products Salix Pharmaceuticals has reported that its total product revenue was $60.6 million for the fourth quarter of 2008, compared to $39.1 million for the fourth quarter of 2007.[More...]

BRIEF: Triangle Stocks Took a Beating: Salix Posted Best Results of 25 Companies; 13 Outperformed the S&P 500

Thu, 01 Jan 2009 14:16:00 GMT

Jan. 1--It was a dismal year for local stocks.
Of 25 public companies based in the Triangle, only three saw their share prices rise in 2008.
Salix Pharmaceuticals was the Triangle's top performer, logging a 12 percent gain.

[More...]

Salix Pharmaceuticals Secures Additional Intellecutual Property Relating to Rifaximin

Tue, 03 Nov 2009 14:50:00 GMT

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No.
Salix has an exclusive license from Alfa Wassermann, S.p.A., to use, sell, have sold and import licensed rifaximin products, which the Company markets in the United States under the trade name XIFAXAN®.
The U.S. Patent and Trademark Office also issued U.S. Patent No.

[More...]

Salix Pharmaceuticals Reports 2Q2009 Results Updates Full Year Guidance

Mon, 10 Aug 2009 20:05:00 GMT

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the second quarter ended June 30, 2009.[More...]

StockPreacher.com Issues Trading Outlook for ViroPharma Inc.

Tue, 04 Aug 2009 10:46:00 GMT

StockPreacher.com announces an investment report featuring biopharmaceutical company ViroPharma Inc. . The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.[More...]

Salix Pharmaceuticals to Present at BMO Conference

Wed, 29 Jul 2009 10:58:00 GMT

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at the BMO Capital Markets Focus on Healthcare Conference in New York, NY on Wednesday, August 5 at 3:30 p.m. ET.[More...]

Salix Pharmaceuticals Announces 2Q2009 Financial Results Conference Call and Webcast

Mon, 27 Jul 2009 10:57:00 GMT

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will report second quarter 2009 financial results following the close of the U.S. financial markets on Monday, August 10, 2009.[More...]

Salix’s Once-Daily APRISO Demonstrates Long-Term Safety in Patients for Maintenance of Remission from Ulcerative Colitis

Tue, 02 Jun 2009 13:05:00 GMT

Data was announced today that demonstrated Salix Pharmaceuticals’ (NASDAQ:SLXP) APRISO™ (mesalamine) 0.375g extended-release capsules had a favorable safety profile in patients in remission from ulcerative colitis (UC) for up to 24 months. APRISO is approved for use up to six months. The majority of treatment-emergent adverse events were mild or moderate in intensity, and were similar to what was seen during the 6-month phase 3 trials. The study, which is the first to examine the long-term safety profile of APRISO, was presented at the Digestive Disease Week (DDW) annual meeting in Chicago, Illinois.[More...]

Salix's Once-Daily APRISO Demonstrates Long-Term Safety in Patients for Maintenance of Remission From Ulcerative Colitis

Tue, 02 Jun 2009 12:56:00 GMT

CHICAGO, IL -- -- 06/02/09 -- Data was announced today that demonstrated Salix Pharmaceuticals' APRISO 0.375g extended-release capsules had a favorable safety profile in patients in remission from ulcerative colitis for up to 24 months. APRISO is approved for use up to six months. The majority of treatment-emergent adverse events were mild or moderate in intensity, and were similar to what was seen during the 6-month phase 3 trials. The study, which is the first to examine the long-term safety profile of APRISO, was presented at the Digestive Disease Week annual meeting in Chicago, Illinois.[More...]

Positive Results from Salix Pivotal Phase III Study of Rifaximin for the Prevention and Maintenance of Remission of Hepatic Encephalopathy (HE) Presented at Digestive Disease Week (DDW)

Mon, 01 Jun 2009 10:56:00 GMT

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the presentation of new data from its Phase III pivotal clinical trial evaluating the efficacy, safety and tolerability of rifaximin - a non-absorbed (<0.4%), gut selective antibiotic - in adult patients with hepatic encephalopathy (HE). These data, presented during two oral sessions at the annual meeting of Digestive Disease Week (DDW) being held this week in Chicago (May 30-June 4, 2009), demonstrated that rifaximin significantly reduced the risk of HE-related hospitalizations in patients with previous episodes of HE and showed a highly significant reduction in the risk of breakthrough HE during the six month study.[More...]

Certain Salix Officers and Directors Adopt 10b5-1 Trading Plans for Stock Options That Are Scheduled to Expire During 2010

Mon, 11 May 2009 14:32:00 GMT

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that certain officers and directors of the Company have adopted predetermined trading plans to exercise expiring stock options over time in accordance with guidelines specified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, and with Salix' policies regarding stock transactions and ownership.
The Salix officers and directors who have entered into Rule 10b5-1 stock trading plans include:
Thomas W. D'Alonzo - Director;

[More...]